Quick Answer
Viridian Therapeutics, Inc.DE reported Long Term Debt of $20.58 million for the year ending 2024.
- Viridian Therapeutics, Inc.DE showed an increase of +1.9% in Long Term Debt from 2023 to 2024.
- This data is from Viridian Therapeutics, Inc.DE's annual report (Form 10-K), filed with the SEC on March 3, 2025.
- XBRL data for this metric is available from 2021 to 2024 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2022: $4.59 million | Q3 2022: $4.61 million | Q1 2023: $4.68 million | Q2 2023: $4.71 million | Q3 2023: $20.00 million | Q4 2023: $20.21 million | Q1 2024: $20.33 million | Q2 2024: $17.49 million | Q3 2024: $20.52 million | Q4 2024: $20.58 million | Q1 2025: $20.69 million | Q2 2025: $12.35 million | Q3 2025: $20.89 million.
- Historical annual values: Fiscal year 2024: $20.58 million | Fiscal year 2023: $20.21 million | Fiscal year 2023: $20.21 million | Fiscal year 2022: $4.65 million | Fiscal year 2021: $0.00.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: